Article 2023 · 6 citations

Radioprotective effects of α2-adrenergic receptor agonist dexmedetomidine on X-ray irradiation-induced pancreatic islet cell damage

Mercantepe, Filiz, Tumkaya, Levent, Mercantepe, Tolga, Rakici, Sema Yilmaz, Ciftel, Serpil, Ciftel, Sedat

Abstract

Comprehensive epidemiological analyses conducted in the last 30 years have revealed a link between radiation and DM. We aimed to determine the effects of dexmedetomidine pretreatment on radiation-induced pancreatic islet cell damage. Twenty-four rats were divided into three groups: group 1 (control group), group 2 (only X-ray irradiation group), and group 3 (X-ray irradiation + dexmedetomidine). We observed necrotic cells with vacuoles accompanying loss of cytoplasm in the islets of Langerhans, extensive edematous areas, and vascular congestions in group 2. In group 3, we observed a decrease in necrotic cells in the islets of Langerhans, and edematous areas and vascular congestion was also reduced. We determined a decrease in beta-cells, alpha-cells, and D-cells in the islets of Langerhans in group 2 compared to the control group. In group 3, beta-cells, alpha-cells, and D-cells were elevated compared to group 2. Ionizing radiation may induce DM. Dexmedetomidine appears to exert a radioprotective effect.

Keywords

Beta-cell Dexmedetomidine Diabetes mellitus Pancreas X-ray irradiation LONG-TERM SURVIVORS DIABETES-MELLITUS CHILDHOOD-CANCER ABDOMINAL RADIATION RISK ENDOCRINE RADIOTHERAPY THERAPY

WoS Categories

Pharmacology & Pharmacy

Sustainable Development Goals

Good Health and Well-being

Citation

Journal: NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Year: 2023
Volume: 396
Issue: 8
Pages: 1827-1836
ISSN: 0028-1298
eISSN: 1432-1912
DOI: 10.1007/s00210-023-02454-0
WoS UID: WOS:000943971800004

Open via DOI